BioCentury | Aug 27, 2020
Distillery Therapeutics

Retrotransposons as acute myelogenous leukemia targets

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Targeting LTR2B and the related LTR2, both long terminal repeat retrotransposons, could treat AML by reducing expression of the lipoprotein component APOCI. Analysis of a The Cancer...
BioCentury | Jun 11, 2020

With $725M Corvidia takeout, Novo gets clinical atherosclerosis asset

...COR-003, Corvidia’s preclinical program to treat acute pancreatitis induced by high triglycerides. That therapy mimics APOCII...
...billion-dollar threshold. An oral formulation was approved last year as Rybelsus. Targets APOCII (APOC2) - Apolipoprotein C-II...
BioCentury | Jan 23, 2020
Clinical News

Akcea, Ionis Phase II hypertriglyceridemia data hint at improved safety for conjugated antisense therapy

Akcea and Ionis announced plans to develop AKCEA-APOCIII-LRx for familial chylomicronemia syndrome based on Phase II safety and efficacy results from hypertriglyceridemia patients. It gives the companies a second shot at marketing an APOC-III antisense...
BioCentury | Dec 21, 2019
Company News

Dec. 20 Company Quick Takes: Genmab partners with CureVac; plus pair of Biogen deals, Ionis, Akcea-Novartis, Paratek and J&J-Taris

CureVac, Genmab to develop RNA-encoded antibody Genmab A/S (NASDAQ:GMAB; CSE:GMAB) and CureVac AG have partnered to discover an mRNA-encoded antibody candidate to treat cancer. Genmab will pay $10 million up front and invest €20 million...
BioCentury | Nov 27, 2019
Company News

With shares rising on M&A chatter, Arrowhead points to pipeline moves in 2020

Buoyed by news of this week's takeout of Medicines Co., Arrowhead is riding a wave of investor enthusiasm for RNAi therapeutics that has quintupled the company’s share price this year, and has boosted its valuation...
BioCentury | Oct 7, 2019
Company News

Amid management shakeup, Akcea strikes latest antisense deal

Akcea will bank $250 million up front from a new licensing deal with Pfizer, adding to a balance sheet already fattened by a February deal with Novartis for another antisense oligonucleotide program based on Akcea's...
BioCentury | Sep 24, 2019
Company News

Unexpected shakeup at Akcea comes amid drug launches

Akcea Therapeutics lost roughly $412 million in market cap as the executive team was unexpectedly gutted on Monday. For now, an interim CEO hailing from majority owner Ionis Pharmaceuticals has been installed. The shakeup could...
BioCentury | Sep 7, 2019
Product Development

Regeneron’s evinacumab data could make it the therapy of choice in HoFH

With a cleaner safety profile and better efficacy than marketed agents, Regeneron’s first-in-class evinacumab is poised to become the standard of care for homozygous familial hypercholesterolemia and other rare lipid disorders, including for the hardest...
BioCentury | Aug 7, 2019
Clinical News

Aug. 7 Clinical Quick Takes: Waylivra cuts triglycerides in Phase III; plus Lynparza, Moderna, Athenex and Opthea

Waylivra hits Phase II/III endpoint in FPL Akcea Therapeutics Inc. (NASDAQ:AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said Waylivra volanesorsen cut serum triglyceride levels by 88% vs. 22% for placebo (p<0.001) in patients with familial partial...
BioCentury | May 7, 2019
Company News

May 7 Company Quick Takes: Akcea, Bicycle/DDF, Arbutus, Celgene/Sutro, MDGH, Pfizer, Sanofi/Regeneron

Akcea's Waylivra approved in EU The European Commission granted conditional approval to Waylivra volanesorsen from Akcea Therapeutics Inc. (NASDAQ:AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) as an adjunct to diet in adult patients with familial chylomicronemia...
Items per page:
1 - 10 of 106